With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid, the randomized CROWNS-2 trial showed.

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Regeneron Pharmaceuticals and Sanofi are collaborating on a Phase 4 clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway ...

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron (REGN) and Sanofi (SNY). Read more here.

Regeneron is having difficulties again with a contract manufacturer, reporting the delay of two FDA regulatory decisions due this month for Eylea.

REGENERON PHARMACEUTICALS (REGN): Free Stock Analysis Report This article Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines originally appeared on Benzinga.com ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced earnings for second quarter that beat the Street estimates. The company's bottom line totaled $1.392 billion, or $12.81 per share. This ...

Regeneron (NASDAQ:REGN), a leading biotechnology firm known for its work in immunology and ophthalmology, reported Q2 2025 earnings on August 1, 2025.